Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03HSA
|
|||
| Drug Name |
Actimab-A
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 2 | [1], [2] | |
| Company |
Actinium Pharmaceuticals New York, NY
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Myeloid cell surface antigen CD33 (CD33) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.